搜尋
CureVac NV
CVAC添加自選
4.660USD
0.0000.00%
收盤 07/02, 13:00（美東）報價延遲15分鐘
1.05B總市值
9.59本益比TTM
關鍵數據
--今開
0.000最高
0.00成交量
9.59本益比TTM
--本益比動
--股利TTM
0.51%換手率
4.660昨收
0.000最低
0.00成交額
6.47本益比靜
1.20市淨率
0.00%股息率 TTM
12.93%ROA
5.72052週最高
1.03量比
162.19M淨利潤
225.17M總股本
0.4858每股盈餘TTM
1.87Beta
16.14%ROE
2.47552週最低
2.03%振幅
99.31%毛利率
1.05B總市值
-3.11回報/風險
2.82%風險率
TradingKey CureVac NV股票評分
單位: USD 更新時間: 2026-01-05操作建議
CureVac NV當前公司基本面數據相對非常健康，增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名40/401位。機構持股佔比非常高，近一月多位分析師給出公司評級為持有。最高目標價為4.68。中期看，股價處於下降通道。近一個月，市場表現較差，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
CureVac NV評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
中性
CureVac NV亮點
亮點風險
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
業績高增長
公司營業收入穩步增長，連續3年增長380.03%
業績轉盈
公司業績轉盈，最新年度盈利美元
估值高估
公司最新PE估值9.59，處於3年歷史高位
機構減倉
最新機構持股23.52M股，環比減少9.09%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉，最新持倉21.87K股
活躍度降低
近期活躍度降低，過去20天平均換手率-0.28
分析師目標
基於
0
分析師
--
評級
5.460
目標均價
+17.17%
漲幅空間
CureVac NV新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
CureVac NV簡介
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
公司代碼CVAC
公司CureVac NV
CEOZehnder (Alexander)
網址https://www.curevac.com/
相關品種
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%熱門品種
52842.500
+588.200 (+1.13%)
29311.400
-487.900 (-1.64%)
7471.500
-4.000 (-0.05%)
14803.000
-552.000 (-3.60%)
68148.000
-1337.000 (-1.92%)
6352.800
+77.400 (+1.23%)
68.344
+0.376 (+0.55%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4121.910
+91.140 (+2.26%)
常見問題
CureVac NV(CVAC)的當前股價是多少？
CureVac NV(CVAC)的當前股價是 4.66。
CureVac NV 的股票代碼是什麼？
CureVac NV的股票代碼是CVAC。
CureVac NV股票的52週最高點是多少？
CureVac NV股票的52週最高點是5.72。
CureVac NV股票的52週最低點是多少？
CureVac NV股票的52週最低點是2.48。
CureVac NV的市值是多少？
CureVac NV的市值是1.05B。
CureVac NV(CVAC)股票的每股收益（EPS TTM）是多少
CureVac NV(CVAC)股票的每股收益（EPS TTM）是0.75。